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Persistent secondary hyperparathyroidism after renal transpla-
nation.
Background. The persistence of secondary hyperparathyroidism
after renal transplantation is frequent and often complicated by
overt hypercalcemia. Recent investigations have shown an effect
of the different vitamin D receptor (VDR) genotypes on parathy-
roid hormone (PTH) secretion in both primary and secondary
hyperparathyroidism. The aims of this study were (i) to assess
whether persistent secondary hyperparathyroidism after renal
transplantation is characterized by any change in calcium-con-
trolled PTH secretion, and (ii) whether different VDR allelic
distributions might play any role on this setting.
Methods. Eighty-one cadaveric renal transplantation recipients,
followed-up for at least 12 months, were checked for PTH, other
primary metabolic and clinical variables, and VDR B/b alleles
(BsmI). In 22 of these the following parameters were evaluated:
(a) kinetics parameters of the Ca-PTH relation curve; (b) verte-
bral mineral density; (c) calcitriol serum levels; (d) PTH-related
peptide serum levels; and (e) urinary hydroxyproline.
Results. According to the stabilised PTH levels (reached by the
third month), the patients were divided in two groups: group A
(N 5 40, PTH , 80 pg/ml) and group B (N 5 41, PTH . 80
pg/ml). Group B differed from group A in that patients had higher
PTH levels at the time of transplantation, were older in age, and
spent more time on dialysis. Group B had increased maximal and
minimal PTH levels, and higher set-point levels than Group A.
The patients with the BB pattern of VDR genotype were charac-
terized by the lowest PTH levels both at time of transplantation
and after stabilization, and lower set point values than patients
with Bb and bb patterns.
Conclusions. Our study suggests that (i) the severity of pre-
existing secondary hyperparathyroidism is the main factor deter-
mining its persistence after renal transplantation, (ii) persistent
secondary hyperparathyroidism is characterized by an autono-
mous pattern of PTH secretion, (iii) the VDR BB genotype seems
to be related to lower PTH levels.
Persistent secondary hyperparathyroidism (SHP) is quite
common even after successful renal transplantation (RTx)
[1–3]. A retained control of parathyroid hormone (PTH)
secretion was first found in transplanted patients by Mc-
Carron and co-workers [4], and an autonomous pattern of
secretion, accompanied by overt hypercalcemia and often
requiring parathyroidectomy (PTX), has been subsequently
reported by many authors [3, 5, 6]. The first aim of the
present investigation was to assess whether the persistence
of SHP after RTx is characterized by any change in PTH
calcium-controlled secretion.
Following the report by Morrison and co-workers of an
association between vitamin D receptor (VDR) gene poly-
morphism in intron 8 (Bb allele) and mineral bone density
[7], a large number of studies have addressed the issue of
the potential role, if any, of VDR allele polymorphism on
other targets of vitamin D activity. In particular, as in
Morrison’s study [7], it was suggested that the b allele was
linked with reduced VDR gene transcription and/or
mRNA stability, and the possibility that a consequent
different regulatory action of vitamin D might play a role
on parathyroid cell proliferation has recently stimulated
research on this issue. In fact, the VDR bb genotype was
found to be associated with sporadic primary hyperpara-
thyroidism by Carling and co-workers [8, 9]. In addition,
the same authors were able to demonstrate a relationship
between the bb genotype and half-maximal inhibition of
Ca-controlled PTH secretion in vitro [10].
On the other hand, conflicting results on the possible
association between VDR genotype and SHP of uremia
have emerged. In fact, some studies demonstrated no
relationship between the VDR B/b allele polymorphism
and the level of SHP in uremic patients [9, 11]. At variance
with these results, in a recent investigation performed on a
group of hemodialyzed patients, Fernandez and co-workers
found that patients with VDR BB genotype have consis-
tently lower PTH levels [12]. In the only published paper
(to our knowledge) addressing the issue of the possible link
between VDR genotype and SHP after RTx, Torres and
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co-workers, studying 34 RTx patients, found lower values of
PTH in the VDR bb genotype group [13].
The second aim of our study was to investigate the
possible role of VDR B/b gene polymorphism on the
evolution of SHP after RTX in a larger group of patients,
and to address the issue of a link, if any, with Ca-controlled
PTH secretion in vivo.
METHODS
Patients
Among the patients transplanted in our center from July
1993 to July 1996, 81 consecutive recipients (59 males, age
18 to 63 years) of a kidney transplant from cadaveric donors
were selected by the following criteria: (1) before RTx none
had been parathyroidectomized or had a history of diabetes
mellitus, (2) after RTx the patients had a stable renal
function (plasma creatinine , 2.0 mg/dl) for at least 12
months, and no significant liver involvement.
The causes of their chronic renal failure were: chronic
glomerulonephritis in 35, interstitial nephritis in 9, polycys-
tic kidney disease in 7, Alport’s syndrome in 4, hypertensive
nephropathy in 4, reflux nephropathy in 3, familiar form of
nephritis different from Alport’s syndrome in 3, lupus
erythematosus syndrome, vasculitis, and post-traumatic re-
nal insufficiency each in 1, and unknown cause in 13.
At the time of RTx, 65 of the patients were on extra-
corporeal dialysis treatment and the other 16 were on
CAPD.
Immunosuppressive therapy consisted of cyclosporine
and prednisone in 70 and cyclosporine, prednisone and
azathioprine or mycophenolate in 11 patients. The mean
prednisone dose in the first six months was 0.4 mg/kg body
wt/day and thereafter the dose was tapered to 0.12 mg/kg of
body wt/day. Cyclosporine was administered in two doses in
order to maintain a trough blood level of about 250 ng/ml
in the first three months, and thereafter about 150 ng/ml
(monoclonal assay). Acute rejection was treated with three
boluses each of 3 mg/kg of i.v. methylprednisolone. Steroid
resistant episodes were treated with OKT3 (5 mg/day over
10 days).
Most of these patients had been treated with vitamin D
derivatives at some time before transplantation; however,
in the three months preceding RTx, 23 patients were on
some vitamin D therapy. All these patients used calcium
salts (carbonate and/or acetate) as phosphate binders. At
the time of RTx, it was possible to assess the serum
aluminum concentration in only 34 of the patients and in
them it was less than 50 mg/liter.
Sixty-eight of these patients were hypertensive after RTx
and their treatment consisted of diltiazem plus clonidine
and/or ramipril. None of them received calcium supple-
mentation, vitamin D derivatives, or other drugs potentially
interfering with calcium metabolism and calciotropic hor-
mones after RTx.
The patients gave their informed consent to the study,
which was approved by the local Ethics Committee.
Study design
In all these patients intact PTH, serum Ca, phosphate
(Pi), total alkaline phosphatase, and body mass index were
checked at time of RTx and after 3, 6 and 12 months.
According to their stabilized PTH serum levels reached
after the third month, the patients were divided into two
groups. Group A had stabilized PTH levels , 80 pg/ml, and
group B had PTH levels . 80 pg/ml (the value of 80 pg/ml
represents the mean 6 2 SD of a population of renal
non-transplanted patients with a comparable degree of
renal function). The two groups were then compared with
regards to the main clinical and metabolic parameters.
All the patients and 80 normal Caucasian subjects,
matched for gender and living in the northeast regions of
Italy, were genotyped for VDR alleles by the BsmI restric-
tion enzyme.
In 22 of the RTx patients (11 in group A and 11 in
group B), after one year of follow-up the following
parameters were evaluated: (a) kinetic parameters of the
Ca-PTH relation curve, using hypocalcemic and hyper-
calcemic infusional tests; (b) vertebral mineral density;
(c) 1,25-dihydroxy-vitamin D serum levels; (d) PTH-
related peptide serum levels; and (e) hydroxyproline,
measured in a urine sample when patients were in a
fasted state. These patients were chosen for their accep-
tance to be submitted to the extended protocol. How-
ever, great attention was paid to their metabolic and
clinical variables being very representative of both the
larger Groups A and B (Results).
Kinetic parameters of RTx patients were compared with
those studied in the 11 control subjects (C). In addition,
two other control groups were considered: the first group,
composed of 16 renal patients (RP1) who were matched
with RTx patients with regards to renal function, was
considered as a proper control group, owing to the even
slightly reduced glomerular filtration rate (GFR) of RTx
patients; the second group, comprised of 16 renal patients
on conservative treatment (RP2) who were matched with
RTx patients with regards to basal PTH levels, was consid-
ered for a better comparison of the possible changes in
PTH secretory parameters in the two groups with a com-
parable degree of SHP.
Parathyroid hormone kinetic parameters
Parathyroid hormone secretion parameters were evalu-
ated with a previously described infusion method [14].
Briefly, the PTH stimulation test was performed by an i.v.
infusion of Na2-EDTA added to 5% dextrose solution plus
20 ml of 1% lidocaine, in an amount of about 37 mg/kg of
body wt, at a constant rate of 4.2 ml/min of solution for 120
minutes. Blood samples were taken from the controlateral
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arm at times 0, 5, 10, 15, 30, 45, 75, 105, 120 minutes to
evaluate ionized calcium and intact PTH. The PTH sup-
pression test was performed between two or five days from
the stimulation test, by infusing i.v. calcium gluconate in an
amount of 8 mg/kg of body wt of calcium element during
120 minutes, for the evaluation of ionized calcium and
intact PTH. The calculation of PTH secretory parameters
was performed according to the four-parameter model
described by Brown [15], as previously described [16].
Vitamin D receptor genotype assessment
Genomic DNA was extracted from blood using a fast
protocol by Talent (Micromix-200). Genomic DNA is
amplified with TaqPolymerase (GIBCO) and gene specific
primers of 30 and 28 bp during cycles. Each cycle consisted
of denaturation at 95°C for one minute and an extension at
72°C for two minutes. The reaction mixture contained 1 3
PCR buffer [67 mM Tris-HCl, pH 8.8, at 25°C, 16 mM
(NH4)2SO4, 0.01% Tween-20], MgCl2 (2 mM). DNTP (200
mM of each), primers (0.5 mM of each) and 2.0 units of
TaqDNA-Polymerase. Amplified DNA was analyzed on a
2% agarose gel, and a single 870 bp was obtained. Then 10
ml of the amplified DNA were restricted with BsmI (3 U) in
the appropriate reaction buffer 13 provided by Boehringer
Mannheim (Mannheim, Germany) according to the suppli-
er’s specification. Restricted DNA was still analyzed on 2%
agarose gel. Three different patterns of bands were ob-
tained and genotype polymorphism was defined as: BB
(absence of restriction site on both alleles), bb (presence of
restriction site on both alleles), or Bb (heterozygous pat-
tern).
Other measurements and statistical analysis
Measurement of bone mineral density was performed by
dual energy X-ray absorptiometry (HOLOGIC 2000) of
lumbar spine (L1-L4) and expressed as grams of hydroxy-
apatite divided by the surface of the projected area in cm2
and as the number of SD from the mean of an age and
sex-matched population (Z score).
PTH was measured by an intact-PTH immunoradiomet-
ric assay (IRAM; Nichols Institute Diagnostics, San Diego,
CA, USA) giving a normal range of between 7 and 55
pg/ml, an intra-assay coefficient of variation of 2.4% and an
inter-assay coefficient of 5.7%.
For 1,25-dihydroxyvitamin D determination a radiore-
ceptorial method (RRA; Nichols) was utilized, which gives
an intra-assay coefficient of variation of 10.0% and an
inter-assay coefficient of 14.0%, with a range in our normal
population of 18 to 54 pg/ml.
PTH-related peptide was measured in plasma, treated
with a protease inhibitor cocktail, by a two-site immunora-
diometric assay (n.v. ,1.3 pMol/liter; Nichols). Hydroxypro-
line in urine was determined by liquid chromatography
(Beckman System Gold) after acid hydrolysis. Serum ion-
ized calcium was evaluated using an ICA 1 ionized calcium
analyzer (n.v. 1.22 to 1.36 mmol/liter; Radiometer, Copen-
hagen, Denmark). Electrolytes and creatinine in serum and
urine were measured by standard methodology.
Statistics were calculated utilizing a t-test for paired data,
ANOVA, regression analysis, parametric and non-para-
metric tests, and chi-square, with Yates correction, using a
statistic package (BMDP) implemented on an IBM 150
MX computer.
RESULTS
Clinical characteristics of parathyroid hormone
The behavior of PTH serum levels after RTx in the
patients studied is shown in Figure 1. PTH levels fell
significantly during the first three months, and remained
Fig. 1. Behavior of parathyroid hormone (PTH)
after renal transplantation (RTx). The thicker
line represents the behavior in the total number
of patients; the two thinner lines represent
respectively group A (lower line) and group B
(upper line). PTH levels fell rapidly during the
first three months and thereafter remained
substantially stable (mean 6 SE; **P , 0.01 vs.
basal values; the differences between the two
groups were all statistically significant by
definition).
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substantially stable thereafter. However, great variability
was observed among the patients, with 40 of them (group
A) reaching stable PTH levels lower than 80 pg/ml (value
representing the mean 6 2 SD of a population of renal
patients with a comparable degree of renal function) and
the other 41 (group B) still maintaining elevated serum
levels. Table 1 shows the main metabolic and clinical
parameters in the two groups of patients at the time of
RTx. The patients with higher stabilized PTH levels were
characterized by higher PTH levels at the time of RTx,
greater time spent on dialysis and older age. No significant
difference was present in the serum levels of both calcium
and phosphate, in gender distribution, and the number of
patients on CAPD treatment at the time of RTx between
the two groups. The behavior of total serum calcium and
phosphate during the follow-up period is shown in Figure 2.
The values of calcium tended to be higher and phosphate
lower in group B for the overall follow-up period. However,
statistically significant differences were reached only at
twelve and six months for calcium and phosphate respec-
tively. During the follow-up period, 10 of the latter group
gradually developed a high degree of hypercalcemia (total
serum calcium higher than 11.5 mg/dl), requiring parathy-
roidectomy in eight of them, performed between 12 and 18
months.
Table 2 shows the main metabolic and clinical parame-
ters in the two groups after 12 months of follow-up. By
definition, the two groups showed different PTH levels. No
other major difference was observed. In particular, no
significant differences in serum calcium, phosphate, and
creatinine levels, cumulative steroid dose, presence of
hypertension and the number of episodes of rejection were
evident.
Results of the extended protocol
Table 3 shows the main basal metabolic and clinical
parameters of the 22 patients (11 for each group) submitted
to the extended protocol. The data show that the two
groups were well representative of the larger original
groups A and B.
Table 4 shows the main parameters in these 22 patients
at the time of the completion of the follow-up period.
Group B patients had, by definition, higher PTH levels. In
addition, group B had a higher hydroxyproline excretion in
Fig. 2. Behavior of total serum calcium and
phosphate in group A (thinner lines) and
group B (thicker lines) in the follow-up period
(mean 6 SE; *P < 0.05 group A vs. group B).
Table 1. Main metabolic and clinical parameters at the time of renal transplantation (RTx) in patients with (group B) and without (group A)
persistent secondary hyperparathyroidism (SHP)
N
Gender
M/F
Age
years
Dialysis
time
months
SCa SPi
PTH
pg/ml
VitD
t/nt CAPD/HDmg/dl
Group A 40 29/11 39.9 6 11.5 23.8 6 14.4 9.81 6 1.04 5.1 6 1.64 168.1 6 141 9/31 10/30
Group B 41 30/11 48.7 6 11.7 44.6 6 37.2 9.96 6 1.27 5.36 6 1.73 538.3 6 375.6 13/28 6/35
P NS , 0.01 , 0.01 NS NS , 0.01 NS NS
Abbreviations are: VitD t/nt, ratio between patients treated and not treated with vitamin D derivatives in the 3 months preceding RTx; CAPD/HD,
ratio between patients on CAPD and HD at the time of RTx (mean 6 SD); SCa, serum calcium; SPi, serum phosphate; PTH, parathyroid hormone.
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fasting urine and ionized calcium serum levels than group
A. Although total serum calcium had a tendency to be
higher in group B, it was not significantly higher. No
significant difference was found in serum creatinine, calcit-
riol and PTH-related peptide serum levels. The mean
values of both bone mineral density and Z score were also
not different between the two groups.
Table 5 shows the PTH secretory parameters in the two
Table 2. Main metabolic and clinical parameters after 12 months of follow-up, in the renal transplanted patients with (group B) and without
(group A) persistent SHP
N
PTH
pg/ml
SCa SPi Creatinine
Steroid
g total
Rejection Hypertension VDR
geneotype
BB/Bb/bbmg/dl Yes/No
Group A 40 55.9 6 21.1 9.84 6 0.54 3.06 6 0.74 1.40 6 0.32 3.10 6 2.31 20/20 32/8 10/17/13
Group B 41 163.4 6 93.9 10.1 6 1.06 2.84 6 0.73 1.68 6 0.62 2.70 6 1.72 22/18 36/5 3/23/15
P dbd NS NS NS NS NS NS 0.06
Data are mean 6 SD; dbd is different by definition. Abbreviations are in Table 1.
Table 3. Main metabolic and clinical parameters at the time of renal transplantation (RTx) in the 22 patients (11 of group A and 11 of group B)
submitted to the extended protocol
N
Gender
M/F
Age
years
Dialysis time
months
Total SCa SPi PTH
pg/mlmg/dL
Group A 11 8/3 40.1 6 11.1 23.6 6 18.6 9.7 6 0.50 5.0 6 1.83 134 6 140
Group B 11 9/2 50.2 6 8.8 55.8 6 32.3 10.0 6 0.88 5.3 6 2.01 445 6 380
P NS , 0.05 , 0.05 NS NS , 0.05
Data are mean 6 SD. Abbreviations are in Table 1.
Table 4. Main parameters of the extended protocol performed 12 months after renal transplantation (RTx), in 11 RTx patients of group A and 11
of group B
N
PTH CTR
Ionized Ca
mmol/liter
OHP/Cr
mg/mg
PTHrP
pmol/l
BMD
g/cm2 Z scorepg/ml
Group A 11 52.8 6 13.5 35.3 6 11.9 1.33 6 0.07 12.2 6 3.33 0.309 6 0.081 0.924 6 0.117 21.05 6 0.94
Group B 11 149.8 6 63.5 33.9 6 15.8 1.46 6 0.15 29.6 6 22.1 0.353 6 0.077 1.011 6 0.159 20.56 6 1.44
P dbd NS , 0.05 , 0.05 NS NS NS
Data are mean 6 SD. Abbreviations are: CTR, calcitriol; dbd, different by definition; Ca, calcium; OHP, urinary hydroxyproline; Cr, creatine; PTHrp,
parathyroid hormone related protein; BMD, bone mineral density.
Table 5. Secretory parameters of PTH in the two groups of renal transplant (RTx) patients, in 16 renal patients matched for renal function (RP1),
in 16 renal patients matched for basal PTH levels (RP2), and in 11 control subjects (C)
N
Ionized Ca
mmol/liter
Basal PTH
pg/ml
Set point
mmol/liter
Sensitivity
%/mmol/liter
PTHmax PTHmin
PTH
basal/max
PTH
min/max
pg/ml %
Group A 11 1.33 6 0.07 52.8h 6 13.5 1.25 6 0.06 370.4e 6 138.1 239.7d,f 6 72.4 20.7 6 9.9 23.6 6 9.1 8.51 6 3.45
Group B 11 1.46b 6 0.15 149.8f 6 63.5 1.39b 6 0.15 336.1e 6 128.3 527.6d,f 6 385.2 68.5b 6 54.5 38.6 6 19.9 17.8c 6 14.5
RP1 16 1.27 6 0.05 42.5 6 22.1 1.24 6 0.05 651.6 6 349.6 138.0 6 56.8 17.5 6 12.3 30.4 6 8.4 12.8 6 7.5
RP2 16 1.25 6 0.09 111.1 6 85.6 1.23 6 0.08 567.5 6 338.2 224.3c 6 127.0 31.4c 6 41.0 45.5c 6 12.9 12.4 6 9.2
C 11 1.26 6 0.04 32.82 6 17.9 1.23 6 0.04 453.6 6 376.7 117.1 6 54.8 8.9 6 5.2 28.2 6 10.3 8.04 6 3.48
Data are: mean 6 SD.
a P , 0.05 vs. all the other groups
b P , 0.001 vs. all the other groups
c P , 0.05 vs. C
d P , 0.01 vs. C
e P , 0.05 vs. RP1 1 RP2
f P , 0.01 vs. C 1 RP1
g P , 0.05 A vs. B
h P , 0.001 A vs. B
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groups studied, compared with 16 renal patients with
comparable renal function, 16 renal patients with compa-
rable PTH basal levels, and 11 control subjects (C). Group
B patients had increased maximal and minimal PTH levels,
as compared to all the other groups. Furthermore, group B
patients only had consistently higher set point levels.
Figure 3 depicts the Ca-PTH sigmoidal relation curve in
the two groups of RTx patients, compared with controls. A
shift to the right and upward in group B patients is evident.
In addition, the set points were well related to the basal
PTH levels only in RTx (Fig. 4A), but such a relationship was
not evident in the other renal patients and controls (Fig. 4B).
Vitamin D receptor genotype and PTH behavior
The VDR allele distribution in the 81 RTx patients was
comparable with that found in the 80 control Caucasian
subjects (Table 6).
When the distribution of the three different VDR geno-
types in the two groups of RTx was considered, the patients
with lower stabilized PTH levels tended to segregate BB
genotype (Table 2), even if the difference of allele distri-
bution between the two groups only approached the level of
statistical significance (P 5 0.06).
When the RTx patients were grouped according to their
VDR genotype, patients with BB pattern were character-
ized by the lowest PTH levels both at the time of trans-
plantation and after stabilization (Table 7). Of the 10
patients who subsequently developed severe hypercalce-
mia, eight of whom were then submitted to PTX, none had
the BB genotype (6 had the Bb and 4 the bb patterns).
In addition, of the patients who were assessed, the
set-point values for Ca-regulated PTH secretion were
significantly lower in BB patients (Table 7).
DISCUSSION
Renal transplantation is effective in correcting the main
causal factors of SHP of uremia, namely phosphate reten-
tion and calcitriol deficiency [17]. Nevertheless, the persis-
tence of SHP after RTx has been reported to occur in a
large proportion of patients [1–3]. In the present series the
rate of occurrence of persistent SHP was about 50%, which
is not different from that reported in other series [18, 19].
As previously reported in the literature [1, 18, 20], the
RTx patients with persistent SHP were characterized by
higher levels of PTH at the time of RTx and a greater
time spent on dialysis. These results support the notion
that the degree of SHP after RTx is largely dependent on
the parathyroid glandular volume reached during the
course of uremia [21], and that the involution of para-
thyroid gland hyperplasia, if this really occurs, takes a
very long time [20].
Among the other factors potentially affecting the degree
of SHP at the time of RTx, in our patients we can rule out
a role for a different distribution of previous CAPD
treatment and previous vitamin D therapy, since only a
small number of patients in both groups were consuming
vitamin D derivatives during the period of time immedi-
ately preceding RTx. With regards to serum aluminium
levels, in most of our patients it was not possible to obtain
its assessment before RTx. However, in those patients who
could be checked, the aluminium levels were in the normal
range, independent of the presence or otherwise of persis-
tent SHP after RTx.
About two decades ago, McCarron and co-workers dem-
onstrated, by infusional methodology, that post-transplan-
tation hyperparathyroidism was characterized by a retained
Fig. 3. Calcium-parathyroid hormone (PTH) sigmoidal relationship in RTx patients without (group A, left panel) and with persistent SHP (group B,
right panel), compared with controls (C). In group B patients a shift of the curve to the right and upward, compared to the controls, is evident.
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control of the parathyroid function [4]. However, subse-
quent studies pointed out that the SHP of RTx patients was
characterized by higher calcium levels for any given basal
PTH value, in both basal conditions [22] and during
calcium infusion [23]. Furthermore, the occurrence of
hypercalcemia after RTx, often requiring PTX, has been
widely reported [2, 5, 6], suggesting an autonomous pattern
of secretion.
In our patients the rate of occurrence of hypercalcemia
after RTx was consistent, since 10 of the 81 patients studied
reached a stable serum calcium level above 11.5 mg/dl
during the follow-up period and 8 of them were submitted
to PTX. In all eight subjects a nodular form of hyperplasia
in all the removed glands was found.
When we assessed PTH secretory parameters in 22 of
these patients (11 for each group), the persistence of SHP
was accompanied by increased values of maximal and
minimal PTH secretion. This was an expected finding,
because these secretory parameters are considered to be an
indirect index of the glandular mass [21, 24] and, as
previously discussed, a greater degree of hyperplasia is
considered the main relevant cause for the persistence of
SHP after RTx. The lesser sensitivity found in group B
might be interpreted as the expected consequence of the
increased parathyroid cell number, as sensitivity is ex-
pressed as the fractional changes of PTH (that is, normal-
ized for PTHmax), the higher is the absolute value of
PTHmax, the lower the fractional change of PTH is ex-
pected to be for a given variation in ionized calcium. The
real cause for the reduced sensitivity in group A, where
PTHmax values were substantially the same as in the RP1
patients, seems less obvious. Merely speculative explana-
tions for this finding could be that the reduced sensitivity
might reflect a reduced rate of recruitment of nonsecreting
parathyroid cells or, alternatively, that the sensitivity of the
single cell (CaR affinity for Ca?) might be lower for some
unknown reason(s).
Fig. 4. Relationship between set point values and PTH basal levels in RTx patients (A) and the RP1 (E) and RP2 (F) (B). A direct linear relationship
is evident in RTx patients (PTH 5 2406.5 1 384.8 3 set point; r 5 0.69, P , 0.001), but not in the other studied groups.
Table 6. Vitamin D receptor (VDR) allele distribution in 81 renal
transplant (RTx) patients and 80 control subjects
VDR genotype
BB Bb bb
N (%)
RTx patients 13 (16.1) 40 (49.4) 28 (34.5)
Controls 17 (21.3) 36 (45.0) 27 (33.7)
Table 7. Vitamin D receptor (VDR) genotype pattern and parathyroid
hormone (PTH) serum levels, both at baseline and after 12 months
after renal transplantation (RTx), and set point (SP) values
BB
13
Bb
40
bb
27
PTH at time of RTx
pg/ml
70.7 6 46.8b 412.0 6 617.0 388.0 6 107.7
PTH 1 year after
RTx pg/ml
53.7 6 20.3a 127.6 6 93.7 114.1 6 87.9
Set point mmol/liter 1.24 6 0.07a 1.36 6 0.14 1.33 6 0.14
[5] [9] [8]
The number of patients where SP values were checked are reported
between brackets.
a P , 0.05 BB vs. Bb 1 bb
b P , 0.01 BB vs. Bb 1 bb
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The most relevant finding was that the calcium-con-
trolled PTH secretion in the patients with persistent SHP
was reset around higher calcium values, with consequently
higher set point and relatively lower sensitivity values. This
pattern of secretion is quite different from that commonly
found in uremic patients, whose set point values are still in
the normal range both before [14] and after [25] dialytic
treatment is started.
On the other hand, increased set point values have been
described in uremic patients with increased calcium levels
due to two opposite conditions: severe hyperparathyroid-
ism or relative hypoparathyroidism with low turnover bone
disease [26–28]. At variance, RTx patients with increased
set points all had increased PTH values. It could be that the
increase in the set point is the result of the underexpression
of the calcium sensing receptor, occurring in the hyperplas-
tic parathyroid glands of severe SHP [29], since the calcium
sensing receptor is thought to be the main factor determin-
ing the set point [30]. The occurrence of hypercalcemia
only after RTX, even in the case of pre-existing altered
calcium-controlled PTH secretion, could be explained by
the enhanced sensitivity of peripheral target organs of PTH
action (particularly the bone), due to the normalization of
the mielieu interior. This interpretation is also in agreement
with Parfitt, who more appropriately defined the secretory
set-point as the target value for calcium homeostatic system
[31].
The clinical implication for these findings is that more
effort must be given to identify patients with severe SHP
and altered calcium-controlled PTH secretion before RTx,
because they are more prone to develop overt and often
severe hypercalcemia following renal transplantation.
The second part of our study faced the problem of a
possible role for the VDR genotype in the evolution of
SHP after RTx.
Many recent studies have stressed the influence of VDR
genotype on bone mass in nonrenal patients [7, 32, 33] as
well as in kidney transplanted patients [13]. In addition to
a possible link between VDR genotype and bone mineral
density, further studies pointed out a relationship between
the different VDR alleles and the occurrence of primary
hyperparathyroidism [8, 9], with the bb genotype being
considered a favorable factor for the occurrence of PTH
hypersecretion. Moreover, the same genotype pattern was
associated with increased set point values for calcium-
controlled PTH secretion in dispersed cells of parathyroid
gland adenoma [10]. Taking these data into consideration,
a not yet defined allele-related effect on PTH secretion has
been proposed, at least in this pathological condition.
On the other hand, to the best of our knowledge, only
two studies dealt with the possible relationship between
VDR genotype and SHP of uremia [11, 12]. The first of the
two was not able to demonstrate any influence of different
VDR allele distribution on the degree of SHP in a cohort
of dialyzed patients [11]. However, due to the short form of
presentation of this paper (letter), much of the information
about other adjunctive factors potentially affecting the
degree of SHP was not given. At variance with this study,
Fernandez and co-workers did find an association between
BB genotype and reduced degree of SHP or, as an alter-
native explanation, between the presence of the b allele and
increased degree of SHP in a group of dialyzed patients,
even after other potentially affecting factors were taken
into consideration [12]. These results were considered in
keeping with the notion that b allele is associated with
lower transcriptional activity and/or mRNA stability, pos-
sibly affecting a different degree of VDR expression and
modulation of the calcitriol effects.
Regarding the possible interaction between VDR geno-
type and SHP after RTx, the only study that indirectly
provides data about this issue is, to our knowledge, that by
Torres and co-workers [13]. In the above paper, which
mainly deals with the potential interactions between VDR
allele distribution and bone mass, PTH serum levels at
baseline, and 3 and 12 months after RTx are reported, with
a lower degree of SHP found in bb genotype, when
compared with the Bb and BB genotypes pooled in one
group.
Our study is at variance with Torres et al’s data [13] and
in agreement with the results of Fernandez et al [12] in that
the BB genotype is associated with lower PTH levels both
before and after RTx. There is no obvious explanation for
the discrepancy between these data, but the number of
patients studied by Torres et al is substantially lower than
that of our and Fernandez et al’s series. In addition, in the
former study, patients with the BB genotype were grouped
together with the Bb genotype due to a particularly low
frequency, and this could have introduced a confounding
factor. In fact, according to our data, no difference was
evident between the bb and Bb genotypes with regards to
PTH levels.
As an additional finding, patients with the BB genotype
also had lower set point levels compared to the other two
genotype patterns. These results suggest that the BB geno-
type or alternatively the absence of b allele might increase
the sensitivity of the parathyroid gland to calcitriol activity,
especially regarding its inhibitory effect on cellular growth
and/or calcium sensitivity. In keeping with this view is the
finding that none of the 10 patients who developed the
most severe form of SHP after RTx had the BB genotype.
In eight of these 10 patients in whom PTX was performed,
a nodular form of glandular hyperplasia was found. It is
also known that the nodular form of parathyroid gland
hyperplasia is characterized by underexpression of the
VDR [34]. Thus, it must be stressed that this condition
probably plays an overwhelming role not only in the
development of the severe SHP, but also in the lack of its
regression after RTx.
On the other hand, it is worth stressing that, when
dealing with the possible influence of the genotype pattern
Messa et al: SHP after RTX and vitamin D receptor genotype 1711
on the phenotypic expression of an indirectly controlled
character, a very large population needs to be explored in
order to reach definitive conclusions. This is especially true
when one faces a multifactorial event, as is the case with the
development of the SHP of uremia.
It must also be kept in mind that the B/b polymorphism
of VDR gene is referred to a non-coding region, which is
linked to other polymorphisms in the 39-untranslated re-
gion of VDR [7]. Furthermore, no data are available as yet
to prove whether the VDR genotype directly or indirectly,
by linkage with other undefined genes, might affect a
different pattern of cellular secretion and/or growth. More
information is needed to better define the link between
gene polymorphism and the described metabolic effects.
For all these reasons, the present results need to be
handled with caution and await further corroboration.
In summary, our study suggests that: (i) the persistence
of SHP after RTx is largely caused by a more severe
pre-existing SHP; (ii) this persistent form of SHP is char-
acterized by an autonomous pattern of PTH secretion,
mainly represented by both higher serum calcium and set
point values; and (iii) the VDR BB genotype seems to be
related in some way to lower PTH levels both before and
after RTx, suggesting partial protection against the devel-
opment of the most severe form of SHP for the patients
who carry this genotype pattern.
Reprint requests to Piergiorgio Messa, M.D., Nephrology, Dialysis, and
Transplantation Unit, Ospedale S. Maria della Misericordia, 33100 Udine,
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